Personalis at 2021 Next Gen Immuno-Oncology Congress US: JUN 28 – JUL 1, 2021


Christelle Johnson

Christelle Johnson, PhD
Senior Field Application Scientist
Personalis, Inc.

Monday, JUN 28 | 11:30 AM EDT

Enabling the Expansive Interrogation of a Tumor & Its Microenvironment from a Single Sample for Translational Research and Precision Medicine  

  • While immune checkpoint blockade has shown a lot of promise, it’s increasingly apparent that predicting response to existing immunotherapies and developing new ones require a more comprehensive approach to tumor immunogenomic profiling.
  • The traditional means of generating information relating to multiple biomarkers involve the use of several assay technologies from various sources which is not only impractical given the limited tumorspecimens, but also due to complications associated with the integration and interpretation of disparate reporting formats, the process can be complex.
  • In this presentation, we will highlight ImmunoID NeXT™, Personalis’ solution to these barriers, and a universal cancer immunogenomics platform that consolidates multiple biomarker assays into one, providing a multidimensional view of the tumor and its microenvironment, from a single
  • We will also highlight our advanced analytics that enable composite biomarker discoveries and more meaningful predictive value for response to various immunotherapies.

Connect with us at Next Gen Immuno-Oncology Congress US 2021